Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-center, randomized, double-blind, placebo-controlled Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic characteristics of nolasiban in healthy adult female subjects in China

Next Previous
Trial Profile

A single-center, randomized, double-blind, placebo-controlled Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic characteristics of nolasiban in healthy adult female subjects in China

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 14 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nolasiban (Primary)
  • Indications Female infertility
  • Focus Adverse reactions
  • Sponsors Yuyuan BioScience Technology

Most Recent Events

  • 13 Jul 2023 According to an ObsEva media release, the company announced that it has recovered full worldwide rights on nolasiban, following the termination of its sub-licensing agreement with Yuyuan BioScience.
  • 13 Oct 2022 According to an ObsEva media release, IND application of Nolasiban has been approved by the Center for Drug Evaluation at the Chinese National Medical Products Administration.
  • 01 Jul 2020 According to an ObsEva media release, Yuyuan has submitted a pre-IND meeting request for nolasiban to the Center for Drug Evaluation at the Chinese National Medical Products Administration (NMPA).This submission represents the first milestone in the process to enable this study in China.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top